SPA
MRNS

Sherbrooke Park Advisers’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Sherbrooke Park Advisers’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-64,721
Closed -$585K – 1267
2024
Q1 		$585K Buy
+64,721
New +$629K 0.11% 311
2023
Q4 		– Sell
-17,539
Closed -$141K – 727
2023
Q3 		$141K Buy
+17,539
New +$146K 0.04% 428

Other funds holding MRNS

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sherbrooke Park Advisers's MRNS Position: Q2 2024 in Review

Sherbrooke Park Advisers sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 64,721 shares — an estimated $585K sold.

Sherbrooke Park Advisers first reported a position in MRNS in Q3 2023 and held it in 2 quarters. The position peaked at $585K in Q1 2024. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

  • Sherbrooke Park Advisers reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 64,721 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $585K.
  • Sherbrooke Park Advisers first reported a position in Marinus Pharmaceuticals, Inc in Q3 2023 and held it in 2 quarters.
  • Sherbrooke Park Advisers's Marinus Pharmaceuticals, Inc position peaked at $585K in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.